Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.
This study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:
1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients;
2. Clinical outcomes;
3. Adverse effects.

开始日期2025-08-01

申办/合作机构

上海市第十人民医院

CTR20251823

/ CompletedN/A

评估受试制剂硫酸艾沙康唑胶囊（规格：0.1g）与参比制剂硫酸艾沙康唑胶囊（CRESEMBA®/康新博®）（规格：100 mg）在健康成年研究参与者空腹及餐后状态下的单中心、随机、开放、两制剂、两周期交叉、单剂量给药生物等效性试验。

采用单中心、随机、开放、两制剂、两周期交叉、单剂量给药设计，分别在空腹和餐后给药条件下，评价华北制药股份有限公司提供的受试制剂（T）硫酸艾沙康唑胶囊（0.1g）和Pfizer Australia Pty Ltd持证的参比制剂（R）硫酸艾沙康唑胶囊（100 mg；商品名：CRESEMBA®/康新博®）在健康人群中的吸收程度和吸收速度的差异，并评价华北制药股份有限公司提供的硫酸艾沙康唑胶囊的安全性。

开始日期2025-06-04

申办/合作机构

华北制药股份有限公司

NCT07191756

/ Active, not recruitingN/AIIT

A Retrospective, Multicenter Cohort Study Comparing the Efficacy and Safety of Amphotericin B Versus Isavuconazole for the Treatment of Mucormycosis: Analysis of Institutional Data and Literature Review

Background:
Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole. However, more real-world data is needed to directly compare how well they work and how safe they are for patients.
What is the purpose of this study? The main goal of this research study is to compare the effectiveness and safety of amphotericin B versus isavuconazole in treating mucormycosis. Investigators will look at which medicine leads to better survival rates and fewer serious side effects.
How will the study be done? This is a retrospective study. This means investigators will look back at information that has already been collected. Investigators will analyze data from the medical records of patients who were treated for mucormycosis at three hospitals. Investigators will also review and combine findings from relevant studies published on PubMed.
What will the researchers measure?
Investigators will measure and compare:
How long patients survived after treatment (survival rates).
Whether the infection was successfully cured or controlled (treatment response).
What kinds of side effects (like kidney problems or liver issues) patients experienced with each medicine.
What are the possible benefits of this study? This study will not directly benefit the participants whose records are reviewed. However, investigators hope that what investigators learn will help doctors make better treatment decisions for future patients with mucormycosis by providing clearer evidence on the best choice of medicine.

开始日期2025-05-15

申办/合作机构

广西医科大学

[+1]

100 项与硫酸艾沙康唑相关的临床结果

登录后查看更多信息

100 项与硫酸艾沙康唑相关的转化医学

登录后查看更多信息

100 项与硫酸艾沙康唑相关的专利（医药）

登录后查看更多信息

751

项与硫酸艾沙康唑相关的文献（医药）

2026-06-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Rapid diagnosis of a mixed pulmonary infection with Rhizopus microsporus, Aspergillus fumigatus, Pneumocystis jirovecii, and Cytomegalovirus in a Lymphoma patient using metagenomic next-generation sequencing: A case report

Article

作者: Qian, Jiao ; Zhu, Qiqi ; Zhang, Qinyi ; Wang, Jiajia ; Wang, Lisha

Immunocompromised patients are at high risk for life-threatening polymicrobial infections, often challenging to diagnose conventionally. We report a 60-year-old male with relapsed angioimmunoblastic T-cell lymphoma, fever, and pancytopenia post-chemotherapy. Chest CT showed scattered inflammation. Bronchoalveolar lavage fluid (BALF) culture grew only Klebsiella aerogenes, but fluorescent staining revealed aseptate hyphae. Metagenomic next-generation sequencing (mNGS) of BALF identified concurrent infections with Rhizopus microsporus, Aspergillus fumigatus, Pneumocystis jirovecii, cytomegalovirus, and SARS-CoV-2 within 48 hours. Targeted therapy with isavuconazole, sulfamethoxazole-trimethoprim, and ganciclovir was promptly initiated. Despite therapy, the patient deteriorated due to profound immunodeficiency and was discharged palliatively. This case highlights mNGS as a rapid diagnostic tool for mixed infections, though clinical correlation remains essential.

2026-04-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Metagenomic next-generation sequencing enables early detection and outcome improvement in perioperative mucormycosis after liver transplantation: A single-center experience

Article

作者: Zhang, Wei ; Wang, Rongrong ; Zhang, Yuntao ; Qi, Jiameng ; Yu, Xinyu ; Wu, Yue ; Liu, Junfang ; Chen, Ying

OBJECTIVES:

Mucormycosis is a rapidly progressive and highly lethal fungal infection in liver transplant recipients, with early diagnosis remaining a major challenge. This study aimed to evaluate the clinical utility of metagenomic next-generation sequencing (mNGS) for early detection and management of perioperative mucormycosis in adult liver transplant patients.

METHODS:

A retrospective analysis was conducted on 539 adult patients who underwent liver transplantation between June 2022 and August 2025 at a single tertiary center. Nine patients with clinically confirmed perioperative mucormycosis, in whom mNGS was the first positive diagnostic tool, were included. Clinical characteristics, diagnostic modalities, antifungal strategies, and outcomes were systematically reviewed.

RESULTS:

Mucormycosis was identified in 1.67% (9/539) of liver transplant recipients. All patients were male with a median age of 51 years. Pulmonary mucormycosis was the most common presentation (n = 5), followed by disseminated (n = 3) and cutaneous infection (n = 1). In all cases, mNGS provided the earliest microbiological evidence, preceding culture and histopathology. Species detected included Cunninghamella spp., Rhizopus microsporus, and Rhizomucor pusillus. The mortality rate of disseminated disease was 100%, whereas localized pulmonary and cutaneous infections had a combined cure or improvement rate of 66.7%. Early targeted antifungal therapy guided by mNGS (amphotericin B formulations combined with posaconazole or isavuconazole) was associated with improved outcomes in nondisseminated cases.

CONCLUSION:

mNGS enables earlier detection of perioperative mucormycosis compared to conventional diagnostic methods and supports timely initiation of targeted therapy. Rapid mNGS-guided intervention may prevent progression to disseminated disease and improve prognosis in liver transplant recipients. Integration of mNGS into the diagnostic workflow is recommended for high-risk patients with unexplained pulmonary or cutaneous lesions.

2026-03-01·JOURNAL DE MYCOLOGIE MEDICALE

Probable disseminated cryptococcosis relapse in a patient with Hodgkin's lymphoma treated with induction therapy resumption and autologous stem cell transplant

Article

作者: Sabouni, Zeina ; Schiano, Jean Marc ; Sevestre, Jacques ; Berger, Pierre ; Deschamps, Anthéa ; Solas, Caroline ; Berro, Simar ; Marchand, Océane ; Bes-Berlandier, Hugo ; Ranque, Stephane ; Choufi, Bachra ; Imbert, Guenièvre ; L'ollivier, Coralie ; Ramtohul, Prithvi ; Guilhaumou, Romain ; Menu, Estelle ; Stellmann, Jan Patrick ; Granata, Angela ; Legrand, Faezeh ; Sohn, Claudine

Cryptococcus species are fungi that primarily cause infections in immunocompromised patients. In cases of hematologic malignancies, it can result in central nervous system and disseminated infections which are associated with high morbidity and case-fatality rate. We present the case of a patient with Hodgkin's lymphoma who experienced a probable relapse in disseminated cryptococcosis during the consolidation phase of treatment. After prolonged induction therapy with amphotericin B and flucytosine, followed by isavuconazole maintenance, the patient achieved a favourable outcome. Six months after relapse of cryptococcosis, the patient underwent autologous stem cell transplantation (ASCT), which resulted in sustained lymphoma remission. The cryptococcosis was successfully contained. This case highlights the need for clinicians to consider reintroducing IT in patients who experience clinical and radiological worsening during the consolidation phase. The patient demonstrated sustained clinical and radiological improvement at seven months post-ASCT, notwithstanding the presence of active cryptococcosis. This suggests that ASCT appears to be safe and feasible when the prognosis of the underlying hematological malignancy warrants its use.

305

项与硫酸艾沙康唑相关的新闻（医药）

2026-02-26

·米内网

【市场】17亿明星药，东阳光药发起冲击

精彩内容 2月26日，CDE官网显示，宜昌东阳光长江药业的艾拉莫德片以仿制4类报产获受理。米内网数据显示，艾拉莫德片在2024年中国三大终端六大市场销售额超过17亿元；2025年Q1-Q3同比增长近30%，是抗炎药和抗风湿药化药TOP1产品。艾拉莫德片主要用于缓解关节肿胀疼痛、改善活动受限等症状，对类风湿关节炎等自身免疫性疾病具有较好的改善作用。近年中国三大终端六大市场艾拉莫德片销售情况（单位：万元）来源：米内网格局数据库艾拉莫德片在近年中国三大终端六大市场（统计范围见文末）销售额均保持双位数增速，2024年超过17亿元；2025年Q1-Q3同比增长近30%，是抗炎药和抗风湿药化药TOP1产品。米内网数据显示，艾拉莫德片有11家企业拥有生产批文，海南合瑞制药、长春海悦药业等10家企业过评，宜昌东阳光长江药业、江西科伦药业、浙江华海药业、湖南方盛制药等34家企业报产在审。东阳光药今年以来报产在审产品来源：米内网中国申报进度（MED）数据库今年以来，东阳光药已有3款产品报产在审，涵盖抗炎药和抗风湿药、全身用抗真菌药等治疗亚类。在中国三大终端六大市场，艾拉莫德片是10亿元级别大品种，注射用硫酸艾沙康唑是潜力品种，2025年Q1-Q3销售额同比增长超过80%；布瑞哌唑在2024年全球销售额是20亿美元级别重磅品种。资料来源：CDE官网、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2026-02-26

·东方消费观察

杨秋华的挑战：上海医药创新发展的突围和升级？

2025年12月25日，上海医药官微发布的消息，12月25日，上海市国资委党委委员、副主任、一级巡视员陈东带队调研上海医药，提出希望上药持续提升企业核心竞争力，提高产业战略能级，科学研判创新药转化态势，找准进口产品国产化的实施路径，并发挥商业优势助力销售扩量；强化投资并购、转化路径、人才激励等体系建设，突出决策效率，为“十五五”创新药产品落地提供战略支撑；培育AI动能，抢抓产业机遇，在研发端、生产端、销售端加快人工智能应用，打造具有全生命周期的“智能制造”。这一要求既是对上海医药过去四年成绩的肯定，也为其未来发展指明了更具挑战性的方向。在这承前启后的关键时刻，掌舵人杨秋华面临着如何带领这家老牌国企实现创新突破的重要命题。四年耕耘：领跑上海上市消费类国企自2021年8月杨秋华出任董事长以来，上海医药在企业转型与创新发展中取得了显著成就。截至2025年9月30日，公司归母净利润增幅达26.96%，在上海市属消费类上市公司中表现突出。这一成绩的取得，源于杨秋华带领团队构建的"战略引领、双轮驱动、全链协同"动态平衡系统的成功运作。在研发投入方面，上海医药展现出了国有企业的远见与魄力。四年来，公司研发投入持续保持在医药工业销售收入的10%左右，2025年前三季度研发投入达到17.29亿元。这种持续高强度的研发投入，为企业的创新发展提供了强劲动力。更值得关注的是，公司创新药业务实现销售收入407亿元，同比增长超过25%，这一数据充分证明了创新投入的产出效率。在创新管线布局上，上海医药展现出了系统性的战略思维。截至2025年三季度，公司拥有在研新药管线57项，其中创新药管线达45项。这些管线涵盖了多个重点领域，包括已提交上市申请的BCD-085项目（靶向IL-17的创新药），处于临床试验阶段的CAR-T细胞治疗项目，以及2026年初获批的马来酸阿伐曲泊帕片等多个重要品种。这种多层次、多领域的研发布局，确保了企业短期、中期和长期发展动力的有序衔接。特别值得一提的是，上海医药在数字化转型方面取得了突破性进展。通过"上药云健康"平台，公司实现了从药品供应到药事服务的全流程数字化闭环管理。这一创新不仅带来了1969.08亿元的商业板块销售收入，更重要的是构建了面向未来的数字化医疗服务生态。同时，CSO业务（合同销售组织）模式的创新实践，帮助公司进口总代业务实现销售收入276亿元，同比增长超14%，展现了企业在商业模式创新上的探索成果。在资本运作方面，上海医药展现出了国企改革的创新思维。通过参与设立上海生物医药并购股权投资合伙企业，收购和黄药业股权等举措，公司既为创新研发提供了资金支持，又实现了业务的协同发展。这种"内外兼修"的双轨创新模式，为国有企业如何平衡创新风险与经营效益提供了重要参考。创新深水区：面临的技术突破难题然而，在亮眼的成绩单背后，上海医药在创新发展方面仍面临着深层次的挑战。随着医药行业创新竞争日趋激烈，企业需要突破现有的创新模式，向更高层级的创新生态迈进。首先，在创新层级方面，上海医药仍以"快速跟进"（fast-follow）策略为主。尽管公司拥有57项在研管线，但真正属于"First-in-class"（首创新药）的项目相对有限。例如，已进入上市申请的BCD-085项目针对的IL-17靶点，国际上已有多个同类药物上市；CAR-T疗法虽然具有创新性，但在靶点选择上仍较为保守。这种创新策略虽然可以降低研发风险，保证短期收益，但难以实现真正的技术引领。其次，在核心技术平台上，上海医药尚未建立起具有全球竞争力的自主技术体系。在生物制药领域，公司在双特异性抗体、ADC（抗体偶联药物）等新兴技术平台上的布局相对滞后；在细胞基因治疗领域，虽然已有CAR-T项目进入临床，但在更前沿的通用型CAR-T、干细胞治疗等方面的布局不足。这种核心技术平台的缺失，使得企业在创新竞争中难以占据制高点。第三，在"卡脖子"技术环节，上海医药仍面临重大挑战。在原料药和高端制剂领域，公司虽然在溴吡斯、硫酸艾沙康唑等品种上取得突破，但在更多高技术壁垒的复杂制剂和原料药方面仍依赖进口。特别是在mRNA疫苗递送系统、长效微球制剂等前沿技术领域，公司的技术积累与国际先进水平存在明显差距。第四，在人工智能等新技术的应用上，上海医药仍处于初级阶段。虽然已经开展了AI药师等应用探索，但在AI药物发现、临床研究数字化等核心环节的应用深度不足。与国际领先药企相比，公司在数字技术与传统研发的深度融合方面还有较大提升空间。最后，在创新体系建设上，上海医药尚未完全突破传统国企的体制机制架构。在研发决策效率、创新激励机制、风险承担机制等方面，与创新型生物科技公司相比仍显保守。这种体制机制上的约束，在一定程度上限制了企业的创新活力。对标海外巨头：多维度需要进一步升级面对创新发展的深层次挑战，上海医药需要在杨秋华的带领下，突破传统体制限制，构建多轮驱动的创新体系。这不仅需要勇气和魄力，更需要系统性的战略谋划和精准的战术执行。在企业创新战略上，上海医药需要实现从"跟随者"到"引领者"的转变。这意味着企业要加大对原始创新的投入力度，特别是在全新靶点和新作用机制的发现上要敢于投入。具体而言，公司可以设立专门的原始创新基金，每年从研发投入中提取一定比例用于高风险、高回报的探索性研究。同时，要建立更加灵活的决策机制，对于具有突破潜力的早期项目，要给予更长时间的耐心和支持。在技术创新体系上，公司需要构建多层次的技术平台。一方面，要继续加强在快速跟进类药物上的投入，保证企业短期内的现金流和盈利能力；另一方面，要着力培育具有颠覆性潜力的技术平台，如基因编辑、细胞治疗、人工智能药物研发等。这些平台的建立不仅要注重自主创新，还要通过并购、合作等方式整合全球创新资源。在突破"卡脖子"技术方面，上海医药需要发挥国企的独特优势。通过联合国内科研院所、高校和企业，组建创新联合体，共同攻关关键核心技术。例如，在高端制剂技术方面，可以联合中国科学院相关研究所、国内领先的制剂企业，共同开发具有自主知识产权的新型递送系统。在生物制药设备、原材料等领域，也可以通过产业链协同创新，逐步实现进口替代。在数字化转型方面，上海医药需要加快人工智能等新技术的深度应用。不仅要继续完善"上药云健康"平台，更要将数字化技术渗透到研发、生产、营销等各个环节。在研发端，可以建立AI药物发现平台，提高新药研发效率；在生产端，推进智能制造，提高生产质量和效率；在营销端，利用大数据分析，实现精准营销和个性化服务。最重要的是，在体制机制创新上，上海医药需要大胆突破。可以探索建立更加符合创新规律的考核激励机制，对创新业务实行分类考核，对基础研究人员实行长周期考核，对创新项目实行风险共担、收益共享的激励机制。同时，要建立更加开放的人才体系，通过建立院士工作站、博士后科研工作站等方式，吸引全球顶尖人才。站在新的历史起点上，上海医药在杨秋华的带领下，正面临着从"国内领先"向"世界一流"迈进的重要机遇。这要求企业不仅要解决当前面临的技术瓶颈，更要构建面向未来的持续创新能力。眼下，上海医药最应该参照的对标药企是日本武田制药（Takeda）。其次，可以部分参考美国强生（Johnson & Johnson）的多元化生态和瑞士诺华（Novartis）的转型战略。外部观察者认为，上海医药如果要像上述企业学习，在对外投资上要从“财务投资”转向“战略并购”：未来的并购应更聚焦于能弥补自身技术短板或带来全球市场准入的资产。在新药研发上，则需要在肿瘤、免疫、罕见病等若干领域深耕，争取做到全球领先，而非全面铺开。最为关键的还是打造跨国整合运营能力：这是目前最大的能力短板，需要提前布局和培养国际化人才。未来的上药可能既要学习武田的转型路径，又要参考强生的生态协同，同时还得借鉴诺华的聚焦策略，才能最终走出一条符合自身发展特色的全球化发展之路。

2026-02-25

·BioSpace

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 6 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased to receive the continued funding from BARDA to support the further development of our novel antibiotic ceftibuten-ledaborbactam, including the preparation of clinical phase 3 studies. We believe that, by addressing the critical unmet medical need for the oral treatment of cUTIs caused by multidrug-resistant bacteria, this candidate holds a strong promise for patients suffering from these severe infections.” Under the terms of the specific Contract[1] with BARDA, upon completion of predefined milestones, Basilea could be reimbursed for a significant proportion of the further development costs required to bring the candidate to market, including the planned phase 3 clinical studies. After the current tranche of USD 6 million, the Contract could provide up to USD 147 million of additional non-dilutive funding. About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales.[2] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options.[3] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48). Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). References This project has been funded in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050. J. A. Karlowsky, M. G. Wise, M. A. Hackel et al. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection. Antimicrobial Agents and Chemotherapy 2022, Nov 15;66(11):e0093422 T. P. Lodise, T. Chopra, B. H. Nathanson et al. Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. Open Forum Infectious Diseases 2022, Jun 24;9(7):ofac315. The content above comes from the network. if any infringement, please contact us to modify.

快速通道合格传染病产品

100 项与硫酸艾沙康唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10643	硫酸艾沙康唑	G01AG J02AC	DB06636

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
隐球菌病	日本	Asahi Kasei Pharma Corp.	2022-12-23
曲霉菌病	加拿大	Avir Pharma, Inc.	2018-12-19
侵袭性曲霉菌病	美国	Astellas Pharma US, Inc.	2015-03-06
毛霉菌病	美国	Astellas Pharma US, Inc.	2015-03-06

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
侵袭性真菌感染	申请上市	日本	Asahi Kasei Corp.	2022-01-30
新型冠状病毒感染	临床3期	美国	Astellas Pharma Global Development, Inc.	2021-03-16
肺曲霉菌病	临床3期	美国	Astellas Pharma Global Development, Inc.	2021-03-16
深部真菌病	临床3期	日本	Asahi Kasei Pharma Corp.	2018-04-16
念珠菌血症	临床3期	美国	Astellas Pharma, Inc.	2007-03-08
念珠菌血症	临床3期	美国	Basilea Pharmaceutica AG	2007-03-08
念珠菌血症	临床3期	中国	Basilea Pharmaceutica AG	2007-03-08
念珠菌血症	临床3期	中国	Astellas Pharma, Inc.	2007-03-08
念珠菌血症	临床3期	阿根廷	Basilea Pharmaceutica AG	2007-03-08
念珠菌血症	临床3期	阿根廷	Astellas Pharma, Inc.	2007-03-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2025	N/A	急性髓性白血病	8,068	Posaconazole	襯鏇襯壓鬱膚糧淵夢夢(鑰鬱遞襯積憲鹹獵醖觸) = 糧齋鬱襯網鑰窪鏇鹹網糧鬱網壓壓糧構餘積願 (積積齋壓鏇觸積繭夢醖 ) 更多	积极	2025-12-06
				Voriconazole/Isavuconazole	襯鏇襯壓鬱膚糧淵夢夢(鑰鬱遞襯積憲鹹獵醖觸) = 餘願積鹽構糧選鹽鹽獵糧鬱網壓壓糧構餘積願 (積積齋壓鏇觸積繭夢醖 ) 更多
1480 (ASH2024)	N/A	急性髓性白血病	295	Isavuconazole	壓觸繭齋餘遞齋簾齋築(鬱築壓鏇淵鹹餘鹽憲觸) = 窪壓範壓窪願鹹醖鏇鹽觸醖顧繭鏇遞衊憲願醖 (範膚簾齋餘簾選壓糧蓋 ) 更多	积极	2024-12-07
				Voriconazole	壓觸繭齋餘遞齋簾齋築(鬱築壓鏇淵鹹餘鹽憲觸) = 遞餘齋範網襯衊齋築齋觸醖顧繭鏇遞衊憲願醖 (範膚簾齋餘簾選壓糧蓋 ) 更多
NCT04550936 (Pubmed \| Infect Dis Ther)	N/A	-	218	Isavuconazole monotherapy	齋艱鑰選鹹顧範壓鹽壓(鹽觸膚鏇壓網夢鹽衊構) = 45 patients (21%) experienced at least one adverse event (AE) 鹽鏇壓簾膚糧鬱鹽蓋積 (蓋網醖選鹽醖淵壓餘觸 ) 更多	积极	2024-12-01
				Salvage therapy
NCT03816176 (CTgov)	临床2期	侵袭性曲霉菌病 \| 毛霉菌病	31	Isavuconazonium sulfate	壓齋積簾構築齋繭廠淵 = 膚艱構窪鏇膚襯糧網夢選遞願積簾築願網鏇糧 (觸襯範顧廠鏇鑰夢築醖, 淵餘選衊廠築鑰範觸鏇 ~ 獵醖憲夢醖夢鑰獵憲鹽) 更多	-	2023-09-21
EBMT2023	N/A	造血干细胞移植	50	Isavuconazole	鑰顧蓋窪積夢鹹鬱簾鏇(膚獵構選鹽膚壓衊鑰鏇) = No adverse events related to ISA were reported 顧鏇壓膚醖鏇鹽顧範構 (廠鑰顧窪憲餘艱襯蓋願 )	-	2023-04-23
NCT03471988 (Pubmed)	临床3期	真菌病	103	Isavuconazole	襯鏇觸鹹壓壓鬱遞憲製(衊遞鏇壓鹽築顧鏇鹽鏇) = Adverse drug reactions were reported in 32 (61.5%) patients receiving isavuconazole and 23 (85.2%) patients receiving voriconazole 壓製淵廠獵醖窪積鬱鹹 (簾衊簾鏇窪製鹽壓繭鏇 ) 更多	积极	2022-10-25
				Voriconazole
EBMT2022	N/A	造血干细胞移植	166	Isavuconazole for treatment of IFI	獵糧蓋顧夢構積齋範顧(憲獵鏇願襯壓築觸鑰鏇) = 鏇窪積顧膚艱艱艱顧遞壓廠繭獵製廠齋艱顧築 (鏇窪選餘窪艱衊積簾築 ) 更多	-	2022-03-19
				Isavuconazole for off-label prophylaxis	獵糧蓋顧夢構積齋範顧(憲獵鏇願襯壓築觸鑰鏇) = 獵繭餘醖鏇淵艱齋壓糧壓廠繭獵製廠齋艱顧築 (鏇窪選餘窪艱衊積簾築 ) 更多
NCT03019939 (CTgov)	临床2期	急性髓性白血病 \| 中性粒细胞减少 \| 侵袭性真菌感染 ... 更多	65	Isavuconazole	醖憲憲簾醖蓋壓壓廠製 = 醖壓鏇壓醖願艱蓋襯顧廠選鹽襯餘齋網艱願鹹 (淵願壓餘積淵觸襯願齋, 積遞範網廠製選蓋獵範 ~ 艱齋艱遞醖繭願構齋願) 更多	-	2021-09-24
NCT03019939 (Pubmed \| Clin Infect Dis) 人工标引	临床2期	急性髓性白血病 \| 骨髓增生异常综合征	75	Isavuconazole	壓鬱鹹鏇糧選壓鬱蓋糧(夢築壓餘餘襯鹹餘壓糧) = 鏇網襯壓觸膚製憲窪選蓋衊簾製膚壓憲襯觸鏇 (繭鑰構窪蓋繭積鹽餘鏇 )	积极	2021-05-18
				venetoclax+Isavuconazole	壓鬱鹹鏇糧選壓鬱蓋糧(夢築壓餘餘襯鹹餘壓糧) = 夢齋壓網繭遞膚衊餘襯蓋衊簾製膚壓憲襯觸鏇 (繭鑰構窪蓋繭積鹽餘鏇 )